Europe Cancer Vaccines Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Cancer Vaccines Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Cancer Vaccines Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Cancer Vaccines Market Regional Analysis

6.2 Europe Cancer Vaccines Market Revenue 2017-2027 (US$ Million)

6.3 Europe Cancer Vaccines Market Forecast Analysis

7. Europe Cancer Vaccines Market Analysis – by Technology

7.1 Dendritic Cells Cancer Vaccines

7.1.1 Overview
7.1.2 Dendritic Cells Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.2 Recombinant Cancer Vaccines

7.2.1 Overview
7.2.2 Recombinant Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.3 Antigen Cancer Vaccines

7.3.1 Overview
7.3.2 Antigen Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.4 Whole Cell Cancer Vaccines

7.4.1 Overview
7.4.2 Whole Cell Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.5 Viral Vector Cancer Vaccines

7.5.1 Overview
7.5.2 Viral Vector Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. Europe Cancer Vaccines Market Analysis – by Type

8.1 Preventive Cancer Vaccines

8.1.1 Overview
8.1.2 Preventive Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.2 Therapeutic Cancer Vaccines

8.2.1 Overview
8.2.2 Therapeutic Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. Europe Cancer Vaccines Market Analysis – by Indication

9.1 Cervical Cancer

9.1.1 Overview
9.1.2 Cervical Cancer: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.2 Prostate Cancer

9.2.1 Overview
9.2.2 Prostate Cancer: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.3 Other Indications

9.3.1 Overview
9.3.2 Other Indications: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

10. Europe Cancer Vaccines Market Analysis – by End User

10.1 Pediatrics

10.1.1 Overview
10.1.2 Pediatrics: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

10.2 Adults

10.2.1 Overview
10.2.2 Adults: Europe Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)

11. Europe Cancer Vaccines Market – Europe Analysis

11.1 Overview

11.2 Europe

11.2.1 Europe Cancer Vaccines Market Breakdown, by Key Country, 2020 and 2027 (%)
11.2.1.1 Europe Cancer Vaccines Market – Revenue and Forecast Analysis – by Country
11.2.1.1 UK: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.1.1 UK: Europe Cancer Vaccines Market Breakdown, by Technology
11.2.1.1.2 UK: Europe Cancer Vaccines Market Breakdown, by Type
11.2.1.1.3 UK: Europe Cancer Vaccines Market Breakdown, by Indication
11.2.1.1.4 UK: Europe Cancer Vaccines Market Breakdown, by End User

11.2.1.2 Germany: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.2.1 Germany: Europe Cancer Vaccines Market Breakdown, by Technology
11.2.1.2.2 Germany: Europe Cancer Vaccines Market Breakdown, by Type
11.2.1.2.3 Germany: Europe Cancer Vaccines Market Breakdown, by Indication
11.2.1.2.4 Germany: Europe Cancer Vaccines Market Breakdown, by End User

11.2.1.3 France: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.3.1 France: Europe Cancer Vaccines Market Breakdown, by Technology
11.2.1.3.2 France: Europe Cancer Vaccines Market Breakdown, by Type
11.2.1.3.3 France: Europe Cancer Vaccines Market Breakdown, by Indication
11.2.1.3.4 France: Europe Cancer Vaccines Market Breakdown, by End User

11.2.1.4 Russia: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.4.1 Russia: Europe Cancer Vaccines Market Breakdown, by Technology
11.2.1.4.2 Russia: Europe Cancer Vaccines Market Breakdown, by Type
11.2.1.4.3 Russia: Europe Cancer Vaccines Market Breakdown, by Indication
11.2.1.4.4 Russia: Europe Cancer Vaccines Market Breakdown, by End User

11.2.1.5 Italy: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.5.1 Italy: Europe Cancer Vaccines Market Breakdown, by Technology
11.2.1.5.2 Italy: Europe Cancer Vaccines Market Breakdown, by Type
11.2.1.5.3 Italy: Europe Cancer Vaccines Market Breakdown, by Indication
11.2.1.5.4 Italy: Europe Cancer Vaccines Market Breakdown, by End User

11.2.1.6 Rest of Europe: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.6.1 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by Technology
11.2.1.6.2 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by Type
11.2.1.6.3 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by Indication
11.2.1.6.4 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 AstraZeneca

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 GlaxoSmithKline plc.

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Aduro Biotech Inc

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Pfizer Inc.

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Sanofi

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Bristol-Myers Squibb

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Moderna, Inc.

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 OncBioMune Pharmaceuticals Inc.

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 MaxiVAX

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Nouscom

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Europe Cancer Vaccines Market